Nanologica acquires Ardena’s Syntagon Facility to expand API manufacturing

SWEDEN — Nanologica, a life sciences company specializing in silica-based peptides for the pharmaceutical industry, has acquired Ardena’s Syntagon manufacturing facility in Södertälje, Sweden.

The company completed the transaction through a stock deal valued at 8.6 million Swedish kroner (USD 961,000).

Strategic acquisition expands production capacity

The acquisition brings the Södertälje facility and its 45-member workforce under Nanologica’s umbrella.

The site will continue operating as a subsidiary under the Syntagon name, maintaining its established brand presence in the pharmaceutical manufacturing sector.

Annette Roos, who currently serves as chief executive of the Ardena division, will remain in her position following the transaction.

Nanologica announced the deal in a press release on January 29.

Additionally, Jeremie Trochu, Ardena’s chief executive, will join Nanologica’s board pending approval at a special shareholder meeting scheduled for early March.

Facility specialization and client relationship

The Södertälje facility specializes in producing active pharmaceutical ingredients across a wide range of project scales.

The site handles everything from early-stage lead molecules to larger-scale commercial production runs.

Nanologica already maintains a working relationship with the facility, having previously engaged Syntagon as a client for its manufacturing needs.

Leadership perspective on growth

Andreas Bhagwani, Nanologica’s CEO, expressed enthusiasm about the strategic move.

He stated that acquiring Syntagon elevates Nanologica to a completely new level and creates opportunities to accelerate the group’s development trajectory.

The transaction provides the company with access to facilities better suited to its current business operations.

Bhagwani explained that the acquisition delivers critical infrastructure for developing new products.

The facility also complements Nanologica’s existing contract manufacturer of silica, creating a more integrated production ecosystem.

This vertical integration positions the company to respond more quickly to market demands and customer needs.

Financial expectations and historical context

Nanologica anticipates the facility will make a material contribution to its earnings in 2025.

The Syntagon site generated sales of 80 million Swedish kroner (USD 8.9 million) during 2024, demonstrating its established revenue-generating capacity.

The facility has operated since 1999, building decades of expertise in pharmaceutical ingredient manufacturing before Ardena acquired it in 2018.

Ardena’s recent expansion Activity

Ardena, headquartered in Belgium, attracted significant industry attention in October 2024 when it acquired Catalent’s oral solids development and small-scale manufacturing facility in Somerset, New Jersey.

The company paid an undisclosed sum for that site, which previously served as Catalent’s corporate headquarters before the company relocated to Florida.

Novo Holdings completed its USD16.5 billion acquisition of Catalent in December 2024, marking one of the pharmaceutical industry’s largest transactions of the year.